Unveiling the Economic Burden of Untreated Mental Illness

By Staff Writer

October 25, 2023

A Better Understanding of the Financial Burden

In the United States, roughly one in five people will struggle with some form of mental illness in any given year; yet, less than half of those people will obtain the appropriate care. The COVID-19 pandemic has further compounded the absence of effective mental health services, leaving millions of people with unmet treatment needs. Untreated mental illness has consequences that reach beyond the person who suffers from it. These consequences include a decrease in the individual’s quality of life, productivity, and overall health. They may even result in work difficulties or engagement with the legal system. Because of this, individuals, families, and society as a whole are forced to shoulder a tremendous amount of additional financial strain.

The Requirement for Detailed Information

Policymakers need comprehensive data on the financial consequences of untreated mental illness to address this issue effectively. Previous research has explored the financial impact of various mental diseases. However, no study has fully examined the costs of untreated disease. Health insurers, governments, and employers need this data. It helps them understand the total economic burden of untreated mental illness. It also shows the potential cost savings from improving access to and delivering mental health care. 

A Case Study: Indiana

A recent study was conducted in Indiana with the purpose of estimating the economic impact of untreated mental illness in the state. The findings of this study will be used to inform legislation and programs that are designed to address this issue. The research presented a methodology at the societal level to evaluate both direct and indirect costs associated with untreated mental diseases. The research estimated the individual, family, workplace, and community expenses associated with untreated mental disorders. The findings were shocking: it was predicted that Indiana bears a total annual economic burden of $4.2 billion due to untreated mental illness.

Taking Steps to Address the Problem

The importance of early detection, counseling, and access to mental health services and therapies is driven home by these findings. Not only could these approaches increase the productivity of individuals and minimise their need for social services, but they also had the potential to drastically cut the expenses associated with incarceration and homelessness. It has been argued that telehealth might be used as a viable means to improve access to therapy, and recent regulatory changes in Indiana have made it possible for Medicaid to compensate providers for providing telehealth services.

The Duty That Falls on Policymakers

Policymakers have an important part to play in removing obstacles to seeking and getting treatment, such as providing care that is sensitive to cultural norms and addressing the stigma that is associated with seeking therapy. They are able to secure improved long-term outcomes and overall cost savings for health care systems as well as society as a whole when they embrace a comprehensive strategy to recognising and resolving the economic burden of untreated mental illness. This is possible because of the comprehensive nature of the approach.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.